A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Trial Profile

A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Teslexivir (Primary)
  • Indications Condylomata acuminata; Genital warts
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Anaconda Pharma
  • Most Recent Events

    • 29 Nov 2017 Status changed from recruiting to active, no longer recruiting, as reported in an Aviragen Therapeutics media release.
    • 31 Aug 2017 According to an Aviragen Therapeutics media release, the company anticipates to complete the enrolment in this trial in the fourth quarter of calendar year 2017. Top-line safety and efficacy data is expected in the second quarter of calendar year 2018.
    • 04 Apr 2017 According to an Aviragen Therapeutics media release, the company anticipates top-line efficacy data in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top